Fee revenue is increasing, Kadcyla revs will be increasing, cash burn is decreasing, therefore financing needs should be decreasing unless/until they get intl late development, which I hope IMGN avoids due to poor past results when they try to develop internally. More good news, not widely publicized, which is puzzling. Are they trying to keep the share price down???
Apparently Triple Negative BC frequently over-expresses Folate. This might be good news and another potential indication for IMGN853 no? ECYT seems to have some good imaging agents to test for bio-markers. Maybe IMGN should consider using ECYT's imaging agents to identify/select patients for their 853 clinical trials?
never happen, they feel entitled, they love low-priced options and they are not afraid to turn their options into cash.
I am sure the interest charges for borrowing ARNA are very high. They would be wise to buy calls and exit soon, Q1 should be a period of high growth in sales. If not, they could be waiting for OREX, the next failed competitor to launch. ARNA needs to get humping on the Bel-Phen trials to finally kill off these weak competitors!
anything B-cell related (529) will have a high hurdle since some new, good drugs are hitting the market and in mid-late development.
Agree, Sanofi needs to pick up the pace. Looking forward to AMGN developments and more info on the LLY molecules/targets. Some positive comments mentioned on IV board regarding Kadcyla from the SABC.
289 is the drug IMGN needs to put their full effort behind, or find an aggressive, qualified partner that can do a Kadcyla-like job. 853 FOLR seems to be a popular new target, need to see more data.
IMGN's value is the partnerships, technology, John Lambert's discovery team and the pipeline. Executives and all other activities are costs that provide little value/return. IMGN should be a drug and technology development division for an oncology-focused biotech, or pharma firm. Execs are just sucking money, value and time from IMGN shareholders and developments IMO. Based on a rough, sum of the current parts calculation, I think it's worth around $24 in an acquisition now, or within the next 6-12 months. All IMO, not individual investment advice.
Hopefully we will not have to rely on the competency of the head of the HHS for this, we all know about her track record.
I assume this is the list of VVUS longs. Ever wonder who is backing the hedge funds that are short? Do you think it's pharma, competitors, potential acquirers, the Mob, sellers of fat stuff, sellers of smokes...there are so many potential backers with a reason to hurt ARNA. Let's hope the light drives out the darkness. ARNA could help shed some light on the naked shorts, pun intended with a stock dividend. I don't know much about the tactic, but anything that causes a full accounting of the shares would be a positive for investors IMO.
HGSI was trading around $1-2 before the rumors started and the drug never was a big seller from what I recall, so GSK's acquisition was a good deal for HGSI shareholders IMO.
A smart acquirer of IMGN that had patience and the ability to maximize the sum of the parts could make a killing at $14. In fact, one could buy the whole deal, sell off the technology, internal programs and partner molecules and keep the Kadcyla royalties almost for free. This price is a bad joke on the IMGN shareholders thanks to the weak execs and BOD!
I think people are just tired of Junius, tired of the under performance and looking for change. Junius says it was a great year for Immunogen, but the stock is barely up on the year while the related indices are up 50%. IMGN has been a public company since about 1990 and the compound annual growth rate for LT investors is between 0%-1%. Compare that to SGEN, their closest competitor, or other successful oncology companies like CELG.
The only people who have made money on IMGN are the executives. Investors are tired or their shareholder unfriendly attitude and focus on personal wealth over shareholder wealth.
Looks like end of year tax loss selling is going to weigh on IMGN, very disappointing. Fortunately, that should end in 2 weeks and maybe then this POS will go up! Junius and the BOD should be ashamed of their terrible performance for the shareholders and making every effort to turn this situation around, but they don't appear to be qualified. Pien has turnaround experience and there are several large owners that must be putting pressure on IMGN for change. It's difficult to ignore the "value" and just as difficult to remain patient holding a relative under performer when the market is going up.
Liberal's love Govt "investment" and conservatives support business and jobs, so let's get this done. As Sharon said the cost reduction benefits outweigh the costs, pun intended. Free Belviq all around!
yes, management has never expressed an interest in being acquired. If someone comes along with a big offer to buy, or partner, I am sure they would have to consider it, but that does not seem to be the plan.
Unfortunately, these lemmings have apparently squirreled away a seemingly endless amount of cash. Who is funding them and why??? Is this just a short investment, or something else??? What's their end game???
no, that's not what they said. I believe they said they manufactured product for the trials and then handed over the process to the current manufacturer. They are not going into manufacturing, other than to support clinical trials and the company that would manufacture commercial products.
If Kad grows to $6-10BB in sales, that alone would justify the current valuation. They have many good partner opportunities and some interesting internal programs, the problem is the market expects Junius and friends to continue screwing up, moving too slow...so it's a show me stock, heavily shorts and currently out of favor thanks to Dan. If they replace DJ with a proven CEO, or if partners continue progress and the pipeline matures...this is a biotech value stock until a sale or big event.
it's just fermenting pig-dog, not rotting. Right now we can buy a $14-15 bottle, but when a deal eventually gets done, or a new product eventually developed, $25-50 bottles all around! I hope that happens before I grow old and die. Relative performance has been terrible this year, so I will agree a bad smell is in the air and my nose!
I would prefer faster, competition is always coming in this industry, but they have to do it right the first time. A good phase II + an approval in PDP might lead to significant off-label sales and usage in ADP. I still think they should consider partnering, or being acquired if they can get a fair deal. Big P needs new and effective CNS drugs to sell.
Not sure I agree with that, I thought he said 2 years for the phase II, which I agree sounds long. I think they intentionally sacrificing some speed for accuracy by working with a smaller institution to maintain good control over the process, procedures, evaluations, etc. The concern could be that the patient population might not be representative. FDA was highly critical of AVEO for their focus on Eastern European patients/patient centers/institutions. I think they used them to save money and it came back to bite them in the #$%$. I am sure ACAD must have has considered and discussed this with FDA.
I have not been to Europe in several years, but last time I was there, smoking was common. Agree with all of the positive comments, smoking might be a better route into Europe, Bel might work on multiple addictions (good to hear that from some MD's treating patients) and if so, it will be a gold mine for investors.
I once thought Genasense would be a gold mine, but it was not potent enough to downregulate Bcl-2 as was advertised by the fraud CEO. So buyer beware, this is a complex industry fraught with peril, risk, exaggeration and once in awhile great reward- see PCYC for a drug that actually does downregulate Bcl-2.
Ed or Ted is not doing such a great job on SGEN, he has a price target of $26. I will stick with Thomas Wei, he's the only Biotech analyst I trust for accuracy and independence. The others are either inaccurate, or corrupt IMO with 20+ years of following the industry.